Literature DB >> 15576331

Characteristics of the caspase-like catalytic domain of human paracaspase.

Scott J Snipas1, Eric Wildfang, Tamim Nazif, Leif Christensen, Kelly M Boatright, Matthew Bogyo, Henning R Stennicke, Guy S Salvesen.   

Abstract

Human paracaspase has been predicted to be a member of the protein structural fold that encompasses protease clan CD. To determine whether paracaspase has catalytic activity we have expressed the region corresponding to the catalytic domain and used protease activity-based chemical probes to profile the putative active site. A leucine-based acyloxymethyl ketone probe that covalently labels cysteine proteases discloses a hydrophobic P 1 preference in the putative active site. The probe covalently labels Cys539, which is not the predicted catalytic site based on structural and sequence comparisons with other clan CD proteases. Using a combinatorial peptide substrate library approach we have been unable to detect amidolytic activity of paracaspase, implying that if it is a protease it must be very specific. We suggest a switch in the use of catalytic residues to generate an enzyme overlapping the canonical clan CD protease active site.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576331     DOI: 10.1515/BC.2004.142

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  14 in total

1.  Mechanism and specificity of the human paracaspase MALT1.

Authors:  Janna Hachmann; Scott J Snipas; Bram J van Raam; Erik M Cancino; Emily J Houlihan; Marcin Poreba; Paulina Kasperkiewicz; Marcin Drag; Guy S Salvesen
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

2.  Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa.

Authors:  Katrine S Larsen; Henrik Østergaard; Jais R Bjelke; Ole H Olsen; Hanne B Rasmussen; Leif Christensen; Birthe B Kragelund; Henning R Stennicke
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

Review 3.  Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Authors:  Shaun Rosebeck; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Future Oncol       Date:  2011-05       Impact factor: 3.404

Review 4.  Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.

Authors:  Margot Thome; Jean Enno Charton; Christiane Pelzer; Stephan Hailfinger
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-08-04       Impact factor: 10.005

Review 5.  MALT1 protease: a new therapeutic target in B lymphoma and beyond?

Authors:  Linda M McAllister-Lucas; Mathijs Baens; Peter C Lucas
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

Review 6.  Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

Authors:  S Fulda
Journal:  Leukemia       Date:  2014-02-03       Impact factor: 11.528

Review 7.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

Review 8.  Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives?

Authors:  Lara M Kingeter; Brian C Schaefer
Journal:  Cell Signal       Date:  2009-09-19       Impact factor: 4.315

9.  Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation.

Authors:  Ravi S Misra; Jennifer Q Russell; Andreas Koenig; Jennifer A Hinshaw-Makepeace; Renren Wen; Demin Wang; Hairong Huo; Dan R Littman; Uta Ferch; Jurgen Ruland; Margot Thome; Ralph C Budd
Journal:  J Biol Chem       Date:  2007-04-26       Impact factor: 5.157

10.  Masking MALT1: the paracaspase's potential for cancer therapy.

Authors:  Domagoj Vucic; Vishva M Dixit
Journal:  J Exp Med       Date:  2009-10-19       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.